[Current status of vaccination therapy for hypertension].

Hiroyuki Sasamura, Tatsuhiko Azegami, Hiroshi Itoh

Research output: Contribution to journalArticle

Abstract

The renin-angiotensin system (RAS) plays a central role in the control of systemic blood pressure. Since the 1950s, both laboratory and clinical studies have been performed to test the efficacy of vaccines against the RAS for the management of hypertension. Although initial studies using renin vaccines and angiotensin I vaccines were unsuccessful, a recent phase IIa study has shown that vaccination against angiotensin II is effective for the treatment of patients with essential hypertension. Results from animal studies have also suggested that vaccination against the AT1 receptor may be effective not only for lowering blood pressure, but also for the prevention of hypertensive end-organ damage. In the future, the RAS may be an important target for the development of vaccines not only for the treatment, but also for the prevention of hypertension and hypertensive complications.

Original languageEnglish
Pages (from-to)1627-1632
Number of pages6
JournalNihon rinsho. Japanese journal of clinical medicine
Volume70
Issue number9
Publication statusPublished - 2012 Sep
Externally publishedYes

Fingerprint

Vaccination
Vaccines
Renin-Angiotensin System
Hypertension
Blood Pressure
Angiotensin I
Therapeutics
Renin
Angiotensin II

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Current status of vaccination therapy for hypertension]. / Sasamura, Hiroyuki; Azegami, Tatsuhiko; Itoh, Hiroshi.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 70, No. 9, 09.2012, p. 1627-1632.

Research output: Contribution to journalArticle

@article{996e99e4282d409389669195c110d507,
title = "[Current status of vaccination therapy for hypertension].",
abstract = "The renin-angiotensin system (RAS) plays a central role in the control of systemic blood pressure. Since the 1950s, both laboratory and clinical studies have been performed to test the efficacy of vaccines against the RAS for the management of hypertension. Although initial studies using renin vaccines and angiotensin I vaccines were unsuccessful, a recent phase IIa study has shown that vaccination against angiotensin II is effective for the treatment of patients with essential hypertension. Results from animal studies have also suggested that vaccination against the AT1 receptor may be effective not only for lowering blood pressure, but also for the prevention of hypertensive end-organ damage. In the future, the RAS may be an important target for the development of vaccines not only for the treatment, but also for the prevention of hypertension and hypertensive complications.",
author = "Hiroyuki Sasamura and Tatsuhiko Azegami and Hiroshi Itoh",
year = "2012",
month = "9",
language = "English",
volume = "70",
pages = "1627--1632",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "9",

}

TY - JOUR

T1 - [Current status of vaccination therapy for hypertension].

AU - Sasamura, Hiroyuki

AU - Azegami, Tatsuhiko

AU - Itoh, Hiroshi

PY - 2012/9

Y1 - 2012/9

N2 - The renin-angiotensin system (RAS) plays a central role in the control of systemic blood pressure. Since the 1950s, both laboratory and clinical studies have been performed to test the efficacy of vaccines against the RAS for the management of hypertension. Although initial studies using renin vaccines and angiotensin I vaccines were unsuccessful, a recent phase IIa study has shown that vaccination against angiotensin II is effective for the treatment of patients with essential hypertension. Results from animal studies have also suggested that vaccination against the AT1 receptor may be effective not only for lowering blood pressure, but also for the prevention of hypertensive end-organ damage. In the future, the RAS may be an important target for the development of vaccines not only for the treatment, but also for the prevention of hypertension and hypertensive complications.

AB - The renin-angiotensin system (RAS) plays a central role in the control of systemic blood pressure. Since the 1950s, both laboratory and clinical studies have been performed to test the efficacy of vaccines against the RAS for the management of hypertension. Although initial studies using renin vaccines and angiotensin I vaccines were unsuccessful, a recent phase IIa study has shown that vaccination against angiotensin II is effective for the treatment of patients with essential hypertension. Results from animal studies have also suggested that vaccination against the AT1 receptor may be effective not only for lowering blood pressure, but also for the prevention of hypertensive end-organ damage. In the future, the RAS may be an important target for the development of vaccines not only for the treatment, but also for the prevention of hypertension and hypertensive complications.

UR - http://www.scopus.com/inward/record.url?scp=84871870800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871870800&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 1627

EP - 1632

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 9

ER -